Clinical Trial Update: Long Term Follow-Up for RGX-111

View source ↗

Summary

This entry reports a long-term follow-up study for RGX-111 in mucopolysaccharidosis type I and indicates ongoing enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis

Drugs mentioned

• RGX-111

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Mucopolysaccharidosis I | Status: ENROLLING_BY_INVITATION